Stockreport

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management [Seeking Alpha]

Longboard Pharmaceuticals, Inc.  (LBPH) 
PDF Follow Summary Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion, driven by the potential of bexicaserin. [Read more]